# What healthy volunteers revealed about a local effect

- Article ID: research-016
- Product: ACE-083 (ace-083-582)
- Canonical page: https://heritagebiolabs.com/research-library/articles/016-what-healthy-volunteers-revealed-about-a-local-effect
- Product collection: https://heritagebiolabs.com/research-library/products/ace-083
- Product page: https://heritagebiolabs.com/product/ace-083-582
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2018, 2022

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are small chains whose amino acids are connected by peptide bonds. Some influence what happens in nearby cells by binding molecules outside those cells. ACE-083 is a larger follistatin-based fusion protein developed to trap signals in the tissue where it was placed. Its 2018 first-in-human study asked how healthy volunteers tolerated it and whether a selected muscle changed in volume. [1]

The randomized, double-blind study enrolled 58 healthy postmenopausal women. It examined either the rectus femoris, one of the thigh muscles, or the tibialis anterior, a muscle on the front of the lower leg. Investigators compared ACE-083 with placebo and used MRI to track the size of the selected muscle. The largest reported mean gains were about 14.5% in a thigh group and 8.9% in a lower-leg group. These were results for particular study groups. The design used several groups, so the figures do not describe an average response across everyone who took part. [1]

The investigators detected no significant mean change in strength. They reported no serious adverse events and no participant discontinuations attributed to adverse events. An early trial in a small, selected population can help identify immediate tolerability problems. Rare effects and safety during longer exposure require data from larger studies with follow-up designed for those questions. [1]

The healthy volunteers gave researchers a way to observe a direct tissue response without the added variation of a progressive muscle or nerve disorder. Later patient studies had to ask whether the same kind of growth could benefit a muscle affected by disease. That question involves both the condition of the muscle and what the person can do with it. [1] [2]

## Sources

1. Chad E. Glasser et al. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle & Nerve (publication 2018-03-15). <https://pubmed.ncbi.nlm.nih.gov/29486514/>
2. Jeffrey M. Statland et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle & Nerve (publication 2022-05-09). <https://pubmed.ncbi.nlm.nih.gov/35428982/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 004 - ACE-083 and Adipotide.docx; article 16; content SHA-256 4d0cc916ac1d94dc6f3227bcd26f710f50c2219a4c76256cf948aae9c17b9f72.
